Funding Opportunity RFA-NS-25-025 from the NIH Guide for Grants and Contracts. The purpose of this initiative are to accelerate research leading to improved understanding and treatments for Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Responsive applications would propose studies of immunological mechanisms of nerve damage/dysfunction, contributing genetic/epigenetic factors, novel animal/cellular model systems, discovery of novel diagnostic or treatment response biomarkers, novel treatments or mechanisms of action of existing treatments.

Funding Opportunity PAR-25-241 from the NIH Guide for Grants and Contracts. The purpose of this PAR is to support policy research projects that examine new or adapted policies pertaining to tobacco, alcohol, and/or cannabis in the U.S., with a particular focus on how the policy or policies influence tobacco, alcohol, and cannabis use or secondhand exposure among populations experiencing disparities. Funded projects will involve authentic engagement with one or more community organizations with the aim of promoting equity in cancer prevention by addressing tobacco, alcohol, and cannabis use and exposure. The long-term goal is to support tobacco, alcohol, and cannabis policy research studies that will improve health equity and promote cancer prevention.

Funding Opportunity PAR-25-240 from the NIH Guide for Grants and Contracts. The purpose of this PAR is to support policy research projects that examine new or adapted policies pertaining to tobacco, alcohol, and/or cannabis in the U.S., with a particular focus on how the policy or policies influence tobacco, alcohol, and cannabis use or secondhand exposure among populations experiencing disparities. Funded projects will involve authentic engagement with one or more community organizations with the aim of promoting equity in cancer prevention by addressing tobacco, alcohol, and cannabis use and exposure. The long-term goal is to support tobacco, alcohol, and cannabis policy research studies that will improve health equity and promote cancer prevention.

Funding Opportunity PAR-25-170 from the NIH Guide for Grants and Contracts. The purpose of this proposed Notice of Funding Announcement (NOFO) is to support development of biomarkers or clinical outcomes derived from digital health technology (DHT) for use in clinical trials for remote monitoring as primary or secondary endpoints. To improve clinical impact, increase statistical feasibility, and promote standardization, applicants will be expected to develop and test the digitally derived assessments in populations from at least three different diseases or conditions. Partnerships with non-profit patient advocacy organizations will be required.

Funding Opportunity RFA-MD-25-001 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support research training activities in minority health and health disparities research for individuals from diverse backgrounds, including groups underrepresented in biomedical, behavioral, clinical and social sciences research based at domestic institutions. Research experiences would be at domestic institutions and/or at specified international low and middle income country (LMIC) locations for eligible undergraduate students, graduate students, clinical residents, research fellows, and postdoctoral trainees.

Notice NOT-MD-25-004 from the NIH Guide for Grants and Contracts

Notice NOT-MH-25-010 from the NIH Guide for Grants and Contracts

Notice NOT-EB-24-018 from the NIH Guide for Grants and Contracts

Competitive: Genomics England: Company Description Genomics England partners with the NHS to provide whole genome sequencing diagnostics. We also equip researchers to find the caus Cambridge, United Kingdom

Competitive: Medical Research Council: View Vacancy -- MRC Investigator Scientist in Bioinformatics and Genetics LMS 2509 Open Date 28/10/2024, 10:00 Close Date 20/11/2024, 23:55 R London, United Kingdom

Competitive: Oxford Nanopore Technologies: Job Description Oxford Nanopore Technologies is headquartered at the Oxford Science Park outside Oxford, UK, with satellite offices and a commercial Oxford, Oxfordshire, United Kingdom

Competitive: University of Nottingham: Closing Date Monday 09 December 2024 Reference SCI446524 We are inviting applications for a Research Associate/Fellow position to join an exci Sutton, United Kingdom

Notice NOT-MD-25-003 from the NIH Guide for Grants and Contracts

Notice NOT-DK-25-002 from the NIH Guide for Grants and Contracts

Notice NOT-DK-25-001 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-054 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may include Phase 1 and 2 studies of drugs and biologics, feasibility studies of devices, and early studies of surgical, behavioral or rehabilitation therapies. All exploratory trials must contribute to the justification for and provide some of the data required to inform a future trial to establish efficacy (such as a Phase 3, Phase 4 or Pivotal trial). This FOA uses the UG3/UH3 mechanism. Only projects that provide satisfactory progress in the UG3 phase may move to the UH3 phase, as outlined below. For a drug, biologic or device that has not completed a Phase 1/Early Feasibility trial: The UG3 mechanism will be used to plan and execute the Phase I trial(s). If Phase 1 trials are successful, the UG3 will also include the planning phase of a Phase 2 trial. The UH3 mechanism will then support the execution of the Phase 2 clinical trial. Transition to the UH3 will depend on successfully reaching agreed upon milestones.

Negotiable: Oxford Nanopore Technologies: Oxford Nanopore Technologies is headquartered at the Oxford Science Park outside Oxford, UK, with satellite offices and commercial presence in many g Oxford, England

Funding Opportunity PAR-25-081 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity, the National Cancer Institute (NCI) seeks research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate.

Funding Opportunity PAR-25-167 from the NIH Guide for Grants and Contracts. Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences.

£39,950 - £45,275 with benefits, subject to skills and experience : The Francis Crick Institute: We are a multi-disciplinary research group with a mission to understand the factors underlying an organ’s regenerative capacity. London (Central), London (Greater)